Bacillus Calmette-Guréin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer

Journal of Urology

Volumn 184, Issue 5, 2010, Pages 1915-1919

  Nepple, Kenneth G ^a   Lightfoot, Andrew J ^a   Rosevear, Henry M ^a   O'Donnell, Michael A ^a   Lamm, Donald L ^b  

^a UNIVERSITY OF IOWA   (United States)

^b BCG Oncology   (United States)

Author keywords

Interferons; Mycobacterium bovis; Urinary bladder neoplasms; Vitamins

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BCG VACCINE; COLECALCIFEROL; FOLIC ACID; PYRIDOXINE; RECOMBINANT ALPHA2B INTERFERON; RETINOL; VITAMIN; ZINC; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT;

ADD ON THERAPY; AGED; ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYSTOSCOPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONMUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; TREATMENT DURATION; UROGENITAL TRACT CANCER; BLADDER TUMOR; CANCER INVASION; CONTROLLED STUDY; DRUG COMBINATION; HEALTH CARE POLICY; INTRAVESICAL DRUG ADMINISTRATION; PATHOLOGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AGED; ANTINEOPLASTIC AGENTS; BCG VACCINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; NEOPLASM INVASIVENESS; NUTRITION POLICY; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; VITAMINS;

EID: 77957852856     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.06.147     Document Type: Article

References (30)

1. H. Vainio, E. Heseltine, and J. Wilbourn Priorities for future IARC monographs on the evaluation of carcinogenic risks to humans Environ Health Perspect 102 1994 590
2. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225
3. Z. Kirkali, T. Chan, and M. Manoharan Bladder cancer: epidemiology, staging and grading, and diagnosis Urology 66 2005 4
4. A. Lopez-Beltran, and R. Montironi Non-invasive urothelial neoplasms: according to the most recent WHO classification Eur Urol 46 2004 170
5. T.J. Kemp, A.T. Ludwig, and J.K. Earel Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L Blood 106 2005 3474
6. A. Morales, D. Eidinger, and A.W. Bruce Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors J Urol 116 1976 180
7. D.L. Lamm, B.A. Blumenstein, and E.D. Crawford A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder N Engl J Med 325 1991 1205
8. M.C. Hall, S.S. Chang, and G. Dalbagni Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update J Urol 178 2007 2314
9. A. Morales, P. Ottenhof, and L. Emerson Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette-Guerin J Urol 125 1981 649
10. R.J. Sylvester, A. van der Meijden, and J.A. Witjes High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder Urology 66 2005 90
11. D.L. Lamm, B.A. Blumenstein, and J.D. Crissman Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study J Urol 163 2000 1124
12. A. Bohle, and P.R. Bock Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression Urology 63 2004 682
13. R.J. Sylvester, A.P. van der Meijden, and D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964
14. H.W. Herr, D.D. Wartinger, and W.R. Fair Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup J Urol 147 1992 1020
15. M.D. Melekos, H. Chionis, and A. Pantazakos Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule J Urol 149 1993 744
16. F. Pagano, P. Bassi, and C. Milani A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J Urol 146 1991 32
17. M.A. O'Donnell, and A. Boehle Treatment options for BCG failures World J Urol 24 2006 481
18. D.L. Lamm, D.R. Riggs, and J.S. Shriver Megadose vitamins in bladder cancer: a double-blind clinical trial J Urol 151 1994 21
19. B.R. Konety, J.P. Lavelle, and G. Pirtskalaishvili Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo J Urol 165 2001 253
20. M.B. Schabath, M.R. Spitz, and S.P. Lerner Case-control analysis of dietary folate and risk of bladder cancer Nutr Cancer 53 2005 144
21. M.J. Becich, S. Carroll, and T.L. Ratliff Internalization of bacille Calmette-Guerin by bladder tumor cells J Urol 145 1991 1316
22. E.C. de Boer, W.H. de Jong, and A.P. van der Meijden Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer A flow cytofluorometric analysis Urol Res 19 1991 45
23. Y. Luo, X. Chen, and T.M. Downs IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy J Immunol 162 1999 2399
24. N. Kayagaki, N. Yamaguchi, and M. Nakayama Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs J Exp Med 189 1999 1451
25. N.A. Fanger, C.R. Maliszewski, and K. Schooley Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) J Exp Med 190 1999 1155
26. K. Pryor, P. Stricker, and P. Russell Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells in vitro Cancer Immunol Immunother 41 1995 309
27. R.W. Glashan A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder J Urol 144 1990 658
28. A.S. Belldegrun, J.R. Franklin, and M.A. O'Donnell Superficial bladder cancer: the role of interferon-alpha J Urol 159 1998 1793
29. F.N. Joudi, B.J. Smith, and M.A. O'Donnell Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer Urol Oncol 24 2006 344
30. U.E. Studer, S. Jenzer, and C. Biedermann Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors Final analysis of a prospective, randomized multicenter trial in Switzerland Eur Urol 28 1995 284